0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2006;296(19):2289. doi:10.1001/jama.296.19.2289.
Text Size: A A A
Published online

MEN'S HEALTH

A JAMA THEME ISSUE

Edited by Phil B. Fontanarosa, MD, MBA, and Helene M. Cole, MD

TREATMENT OF LOWER URINARY TRACT SYMPTOMS

Men with overactive bladder and other lower urinary tract symptoms are often treated with an antimuscarinic agent or an α-adrenergic receptor antagonist; however, monotherapy is not always effective. In a randomized 12-week trial, Kaplan and colleagues investigated the efficacy and safety of tolterodine extended release (an antimuscarinic), tamsulosin (an α-adrenergic receptor antagonist), both drugs, or placebo in men with overactive bladder and benign prostatic hypertrophy. The authors found that men who received combination therapy were significantly more likely to report treatment benefit than men receiving either monotherapy or placebo. All active treatments were well tolerated and the incidence of acute urinary retention was low.

ADJUVANT RADIOTHERAPY FOR ADVANCED PROSTATE CANCER

The optimal management of patients with advanced prostate cancer detected at radical prostatectomy is not known. Thompson and colleagues assessed metastasis-free survival of men with advanced prostate cancer who were randomly assigned to either receive external beam radiotherapy to the prostatic fossa or usual care with observation. During a median follow-up time of nearly 15 years, the authors found that compared with usual care, adjuvant radiotherapy did not improve metastasis-free survival or overall survival but was associated with reduced risk of biochemical relapse and disease recurrence.

PSA SCREENING AMONG ELDERLY MEN

Prostate cancer screening by prostate-specific antigen (PSA) level is not recommended for men with limited life expectancies; however, few data exist on actual screening practices. Walter and colleaguesArticle analyzed data from 597 642 male veterans aged 70 years and older who received care at Veterans Affairs facilities during 2002 and 2003. The authors found little evidence that PSA screening rates declined with advancing age and worsening health status. Among men aged 85 years and older, 34% in the best health and 36% in worst health had a PSA test performed. In an editorial, AlbertsenArticle discusses key issues to consider before ordering a PSA test.

MIDLIFE RISK FACTORS AND HEALTHY SURVIVAL

In a prospective cohort study of Japanese American men, Willcox and colleagues assessed whether certain biological, lifestyle, and sociodemographic risk factors present in midlife are associated with overall survival and exceptional survival to age 85 years free of 6 major chronic diseases and physical and cognitive impairment. The authors found that high grip strength and the absence of overweight, hyperglycemia, hypertension, smoking, and excessive alcohol consumption in middle-age were associated with both overall and exceptional survival in this cohort men of Japanese ancestry.

EFFECTS OF TESTOSTERONE REPLACEMENT ON THE PROSTATE

Testosterone replacement therapy (TRT) is often prescribed to ameliorate the effects of age-related declines in testosterone, but the effects of TRT on prostate tissue are not clear. Marks and colleagues assessed prostate tissue androgen levels, histology, and cellular functions in men with late-onset hypogonadism, who were randomly assigned to testosterone or placebo injections. The authors found that 6 months of TRT normalized serum androgen levels but was not associated with significant changes from baseline in prostate tissue androgen levels or other prostate-related outcomes.

MEDICAL NEWS & PERSPECTIVES

Researchers are working to identify genetic, anatomical, and functional differences in the male vs the female brain and to determine how such differences play out in disease risk and response to drugs.

CLINICIAN'S CORNER

Addressing the unique primary health care needs of men who have sex with men (MSM).

FATHERHOOD AND HEALTH

Potential influences of fatherhood on health.

MALE BIOLOGICAL CLOCK

Clinical implications of the male biological clock.

IMPROVING MEN'S HEALTH

Evidence and opportunities for improving men's health are discussed by this issue's editors.

AUDIO COMMENTARY

Dr DeAngelis summarizes and comments on this week's issue. Go to http://jama.ama-assn.org/misc/audiocommentary.dtl.

JAMA PATIENT PAGE

For your patients: Information about prostate cancer.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.